Palobiofarma S.L., una empresa biofarmacéutica dedicada al descubrimiento y desarrollo de fármacos innovadores para enfermedades huérfanas, ha anunciado hoy el logro de varios hitos importantes en ...
Read moreAptaTargets signed in May 2025 a licensing agreement with Merck for the clinical development and global commercialisation of ApTOLL, an aptamer with neuroprotective effect for the treatment of ischaem...
Read moreIn bioanalytical workflows, biomarkers serve as quantifiable proxies for biological processes, disease states, or therapeutic responses. Still, the rapid evolution of drug discovery and clinical devel...
Read moreRecently approved by the European Medicines Agency, RESTORE will evaluate iadademstat’s ability to raise fetal hemoglobin (HbF) in adult patients with SCD
Read moreAutomation in pharma promises faster cycles, cleaner records, and lower cost. It can deliver. But the same digital workflows that cut review time from fourteen days to five can also manufacture findin...
Read morePreliminary data from the ongoing Phase Ib trial combining iadademstat with azacitidine and venetoclax in newly diagnosed, unfit AML patients showed a 100% overall response rate
Read moreThe net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&Green
Read more53Biologics ha sido distinguida hoy con el Premio Pyme del Año 2025 de Valladolid, un reconocimiento otorgado por Banco Santander y la Cámara de Comercio de Valladolid, en colaboración con la Cáma...
Read moreJoan Puig: “In inorganic growth in Europe, cultural difference is one of the most important challenges”.
Read more100% Overall response rate (ORR) in triple combo study with azacitidine and venetoclax in newly diagnosed AML patients
Read moreBiotechnology is rapidly transforming the pharmaceutical landscape—yet its industrialisation presents challenges that require coordinated technical, regulatory and strategic action.
Read moreBiopharmaceutical company Oniria Therapeutics, Vall d’Hebron Institute of Oncology (VHIO) and Institut Català d’Investigació Química (ICIQ) will work together on the regulatory preclinical phas...
Read more